Documents transmis le 18/07/2023 - Trientine Waymade 200 mg, gélule

PUBLIÉ LE 21/07/2023

Trientine Waymade 200 mg, gélule - 13/09/2022 - Décision d'autorisation de mise sur le marché

Trientine Waymade 200 mg, gélule - 2021 - Module 2.5 - Clinical overview

Trientine Waymade 200 mg, gélule - 2021 - Reference member state end of procedure DCP

Trientine Waymade 200 mg, gélule - 2021- Concerned member state comments on day 70 preliminary assessment report to be sent at day 100 at the latest

Trientine Waymade 200 mg, gélule - 2021- Concerned member state comments on day 120 assessment report to be sent at day 145 at the latest

Trientine Waymade 200 mg, gélule - 2021 - Medicinal products for human use - Volume 2B - Module 1.2: Administrative information - Application form

Trientine Waymade 200 mg, gélule - 2020 - Decentralised procedure RMS day 70 preliminary assessment report - Overview and list of questions

Trientine Waymade 200 mg, gélule - 2020 - Decentralised procedure RMS day 120 draft - Assessment report - Overview and list of questions

Trientine Waymade 200 mg, gélule - 2020 - Decentralised procedure RMS day 180 draft - Assessment report - Overview and list of questions

Trientine Waymade 200 mg, gélule - 2021 - Particulars to appear on the outer packaging and the immediate packaging - Bottle

Trientine Waymade 200 mg, gélule - 2021 - Particulars to appear on the outer packaging and the immediate packaging - Carton

Trientine Waymade 200 mg, gélule - 2021 - Decentralised procedure RMS final assessment report - Overview and list of questions

Trientine Waymade 200 mg, gélule - DE/H/6991/001/DC - Day 195 FR no comments

Trientine Waymade 200 mg, gélule - 2021 - Decentralised procedure - Responses to day 70 and day 100 comments - Module 1

Trientine Waymade 200 mg, gélule - 2021 - Module 2.4 - Non clinical overview

Trientine Waymade 200 mg, gélule - 2021 - Package leaflet : Information for the patient

Trientine Waymade 200 mg, gélule - 2021 - Summary of product characteristics